Fig 1: Immunohistochemistry was used to detect the coincidence degree of ACTA1 expression with tumor cells in OSCC serial sections (A). The expression of ACTA1 was higher in the tumors of patients with T3 and T4 stages (p = 0.02816) (B). There was no statistically significant difference in lymph node metastasis (p = 0.1405) (C). The expression of ACTA1 in the tumor cells of the PNI+ group was significantly higher than that of the PNI− group (p = 0.0151) (D). The group with high ACTA1 expression had a worse prognosis (p = 0.0468) (E).
Fig 2: The ratio and absolute number of human CD3+ T cells, CD3+CD4+ helper/inducer T cells, CD3+CD8+ cytotoxic T cells, CD3−CD19+ B cells, and CD3− CD16+ and/or CD56+ NK cells (A) in peripheral blood were analyzed in High-ACTA1 and Low-ACTA1 groups using the BD Multitest™ reagent (B, C) (n = 9 patients were missed), by multiple t-test.
Supplier Page from Abcam for Anti-Actin antibody - Loading Control